Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Localization-related Epilepsy Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed No phase listed Observational

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

NCT03054961
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Near-infrared spectroscopy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

NCT01091662
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Tucson, Arizona • Conway, Arkansas • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery

NCT04986683
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Brain magnetic resonance imaging, Neuro-psychology testing
Diagnostic Test · Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
3 Years to 19 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 20, 2026, 5:43 AM EDT
Not listed No phase listed Observational

Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy

NCT04879433
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Not listed
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

NCT00113815
View directory record Official record
Conditions
Partial Seizure Disorder, Epilepsy, Seizures
Interventions
topiramate, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 24 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Localizing Epileptic Networks Using MRI and iEEG

NCT04649008
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
Interventions
3T Magnetic Resonance Imaging, Intracranial electroencephalography recordings, 7T Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

NCT05081518
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Surgery as a Treatment for Medically Intractable Epilepsy

NCT01273129
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 20, 2026, 5:43 AM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 5:43 AM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
View directory record Official record
Conditions
Focal Epilepsy
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 20, 2026, 5:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain P-gp and Inflammation in People With Epilepsy

NCT01663545
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429
View directory record Official record
Conditions
Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
16 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
106
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 20, 2026, 5:43 AM EDT
Completed No phase listed Observational

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008
View directory record Official record
Conditions
Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions
Not listed
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
16 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Spatial Scene Recognition Memory in Epilepsy Surgery

NCT07580183
View directory record Official record
Conditions
Focal Epilepsy, Temporal Lobe Epilepsy, Medically Refractory Epilepsy, Memory Disorders, Epilepsy Comorbidities, Epilepsy Intractable, Epilepsy Surgery, Epilepsy, Temporal Lobe, Memory Deficits, Memory Disorder, Spatial, Memory Dysfunction, Spatial Perception
Interventions
Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I)
Behavioral · Device · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
Sacramento, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Sleep Architecture & Cognition in Focal Epilepsy

NCT05794295
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Acoustic Stimulation (AS), SHAM Stimulation
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy

NCT01703143
View directory record Official record
Conditions
Epilepsy
Interventions
Laser ablation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655551
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 20, 2026, 5:43 AM EDT